Sobi (Swedish Orphan Biovitrum AB) / Dova Pharmaceuticals, Inc.
2019 · Acquisition/Merger · $915M · Complete
Announcement Sentiment
75
Strongly positive
Sobi agreed to acquire Dova Pharmaceuticals for $27.50/share or approximately $915 million, with an additional $1.50/share CVR linked to FDA label expansion. Lead asset is Doptelet (avatrombopag) for thrombocytopenia in chronic liver disease and chronic ITP. Sobi completed the acquisition by merger on November 12, 2019. The CVR required FDA approval of Doptelet in chemotherapy-induced thrombocytopenia (CIT) by December 31, 2022; that approval was not obtained — the Phase 3 CIT trial reported in 2022 and avatrombopag remains approved only in chronic liver disease and chronic ITP — so the contingent $1.50/share milestone lapsed.